Ads
related to: anti-cytokine therapy for cancer success- Treatment Modifications
View Treatment Modifications
To Manage Adverse Reactions.
- View All Indications
Explore All Indications And See
The Range Of Treatment Options.
- See Dosing Schedules
Find Dosing Information For This
1L NSCLC Dual I-O Option Today.
- Explore Patient Programs
Visit Access And Support Site
& View Resources For Your Patients.
- Treatment Modifications
Search results
Results From The WOW.Com Content Network
Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen. Dendritic cells are antigen-presenting cells (APCs) in the mammalian immune system. [15] In cancer treatment, they aid cancer antigen targeting ...
A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. [1] The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.
Bi-specific T-cell engager (BiTE) is a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells ' cytotoxic activity, against cancer cells.
The use of monoclonal antibodies in cancer therapy was first introduced in 1997 with rituximab, an anti-CD20 antibody for treatment of B cell lymphoma. [15] Since then several monoclonal antibodies have been approved for treatment of various haematological malignancies as well as for solid tumours. [16] [17]
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. [ 1 ] Hence, anti-IL6 agents have been sought.
A lower incidence of hypothyroidism was observed in a trial of combined B cell depletion and immune checkpoint inhibitor treatment compared with studies of immune checkpoint inhibitor monotherapy. [30] This holds promise for combining check point inhibitor therapy with immunosuppressive drugs to achieve anti-cancer effects with less toxicity.